Research programme: anticancer antibodies - MorphoSys/Bayer
Latest Information Update: 24 Mar 2010
At a glance
- Originator Bayer; MorphoSys
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 May 2003 Preclinical trials in Cancer in USA (unspecified route)